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ABSTRACT
Purpose: Elbow tendinopathies are common conditions that typically last 6 to 24 months. There is no clear consensus in the
literature regarding the most effective management. Platelet-rich plasma (PRP) is an autologous blood product used for elbow
tendinopathies with the aim of enhancing tissue regeneration. The aim of this systematic review was to evaluate the available
evidence on the effectiveness and safety of PRP for reducing pain and physical function in elbow tendinopathies. Methods:
Electronic databases were searched for relevant studies and data were extracted regarding the design, sample characteristics,
interventions, and outcome measures. Each study was critically appraised for methodological quality using a modified tool for
quantitative studies and presented in a narrative summary. Results: The search strategy identified 299 hits related to plateletrich plasma and/or elbow tendinopathies. Five studies met the inclusion criteria; all were randomized controlled trials except one
cohort study. All five studies showed improvements from baseline in pain and physical function with a PRP intervention. One
study and its follow-up study showed significant improvements in pain and function with PRP compared to corticosteroid at 26,
52, and 104 weeks. Two studies compared PRP to whole blood, which did not find sufficient evidence to suggest one is more
effective than the other. A cohort study found PRP was more effective than placebo at 4 and 8 weeks. Three studies reported on
the safety of PRP and found no significant adverse effects. Conclusions: The current literature has some limitations and is
insufficient to provide strong recommendations regarding the use of PRP in elbow tendinopathies over other modalities;
however, these studies suggest that PRP may be more efficacious than corticosteroid injections, but that whole blood injections
may be as effective as PRP.
BACKGROUND
Description of the Condition
Elbow tendinopathies, either medial or lateral in location, may be diagnosed as tennis elbow, golfer's elbow, rowing elbow,
epicondylitis, epicondylosis, epicondylagia, tendonitis, and tendinosis.1,2 For this review, the term “elbow tendinopathies” is used
to allow for a greater level of inclusion.
Elbow tendinopathy refers to "a failure of the normal tendon repair mechanism associated with angiofibroblastic degeneration.”3
Clinically, elbow tendinopathies often present as an overuse injury or following a change in training, technique, or activity. There
is generally local tenderness over the site of the injury and pain with gripping, twisting, and activities that require forearm
strength. Walker-Bone and colleagues found the prevalence of lateral epicondylitis in the general population to be 1.3% and
1.1% for men and women respectively, while medial epicondylitis had a prevalence of 0.6% and 1.1% for men and women
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respectively.4 And while most patients will recover within a year, a typical episode lasts between 6 to 24 months, thus, potentially
presenting significant costs through medical and pharmaceutical intervention and time off work.5
Wide-ranging treatments have been trialed for elbow tendinopathies. Eccentric exercise programs have shown encouraging
results but require further and precise research.6, 7 NSAIDs have insufficient evidence to support or refute their use.8 Low level
laser therapy may reduce pain and disability over the short-term, while repetitive shock wave therapy has some evidence under
well-defined, restrictive conditions only.9,10 Satisfying results of shock wave therapy in the range of 60% have been identified with
common variables such as chronic recalcitrant patients; weekly intervals of repetitive application of 2000 low-energy shock wave
therapy over 3 to 6 weeks; without local anesthesia; and a follow-up of at least 3 months post application.10 Acupuncture has
shown some short term benefit for pain, and surgery has insufficient evidence to support or refute its effectiveness.1,2 While
corticosteroid injection was once considered the gold standard, controversy exists regarding negative side-effects of
corticosteroid injections on tendons, with a recent systematic review on tendinopathies finding that although there is consistent
short-term benefit from corticosteroids, it is worse than other conservative interventions in the long term.11
Description of the Intervention
Platelet-rich plasma (PRP) is an autologous blood product with a higher concentration of platelets than that of whole blood.12 The
use of platelet concentrates in medicine to improve healing is a relatively recent development, facilitated by an increase in the
understanding of their role in inflammation and healing processes. Despite considerable research in the last decade, PRP use
and efficacy remains controversial.13
In the preparation of PRP, blood is taken and an anticoagulant added, which is then centrifuged immediately to separate the
blood into several layers; the desired layer is the “buffy coat” between the red blood cells and platelet-poor plasma, which has a
high concentration of platelets.13 Although the generic term “PRP” is commonly used, variances in the preparation systems exist,
yielding varying end-products.13
PRP is purported to enhance tissue regeneration and healing through high quantities of growth factors released by the
platelets.12 The rationale behind PRP is to reverse the normal proportions of blood such that the quantity of red blood cells is
minimized and the quantity of platelets is maximized.
Previous systematic reviews have looked at various injection therapies for tendinopathies as a whole but have found little
evidence to support PRP because of paucity of trials, methodological flaws, and inconsistent findings.11,14,15,17 Taylor et al
reviewed the evidence for the use of PRP for ligaments and tendons of multiple body areas and concluded that the evidence for
PRP for soft tissue treatments was weakly supported.16 One systematic review has looked at injection therapies (prolotherapy,
polidocanol, whole blood, and PRP) for lateral elbow tendinopathies; however, the authors considered only one study that had
used platelet-rich plasma and therefore meaningful conclusions could not be drawn. 17
Why it is Important to do this Review
With the evident lack of a gold standard treatment for elbow tendinopathies, it is necessary to explore possible treatments and
evaluate the strength of evidence to guide health professionals. With the recent emergence of PRP injections for elbow
tendinopathies, it is important to assess its efficacy, safety, and cost effectiveness, especially considering many insurance
companies do not cover this procedure, and consider whether further research is warranted.
Objective
The aim of this review was to systematically evaluate the evidence regarding the effect and safety of platelet-rich plasma
injections for elbow tendinopathies.
METHODS
Criteria for Considering Studies for this Review
Types of Studies
This systematic review included only quantitative, prospective studies from peer-reviewed journals. Both clinical trials and cohort
studies that had a comparator group were included. Cohort studies were included because of the paucity of clinical trials on the
topic; however, limiting the review to comparison studies adds validity to the meta-analysis. Under the NHMRC Evidence
Hierarchy therefore, this equated to Level II and Level III evidence.18 The meta-analysis focused on studies published in the
English language.
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Types of Participants
Trials were included if they reported subjects with tendinopathies present in either the lateral or medial elbow. Due to the wideranging terminology used in the literature, descriptions of tendinopathy, tendinitis, tendinosis, epicondylitis, epicondylagia,
epicondylosis, tennis elbow, and golfer’s elbow were all considered in the review. Trials that included subjects with tendon
ruptures or post-surgical tendon repairs were excluded. No restrictions were made on subjects’ age or gender.
Types of Intervention
Studies were considered if they reported PRP as one of the interventions being investigated for elbow tendinopathies, regardless
of how many PRP injections were administered. No restrictions were imposed on the type of comparator (eg. corticosteroid,
whole blood) in order to examine the effectiveness of PRP against many existing interventions.
Types of Outcomes
All studies were required to have an outcome measure for pain or self-reported function, as pain and loss of function are the
primary complaints of patients with elbow tendinopathy. No restrictions were placed on how these outcomes should be
measured. The presence of adverse outcomes was of interest, but did not form part of the eligibility criteria.
Search Methods for Identification of Studies
The following databases were searched for relevant studies: Medline, Embase, CINAHL, Cochrane, PubMed and SportsDiscus.
A list of key search terms, grouped into three key concepts, was utilised for literature searching. These three concepts were
combined to capture the most relevant studies.
Concept one: platelet-rich plasma; Concept two: tendinopath* or tendinitis or tendinosis or epicondyl*; Concept three: elbow. The
search was limited (where available) to studies involving humans and those published in the English Language. The reference
lists of included articles were examined for additional studies that may not have been indexed in the electronic databases.
Data Collection and Analysis
Selection of Studies
The titles and abstracts retrieved from the search were examined for relevance. Potentially relevant articles were then obtained
in full text and independently assessed for eligibility.
Assessment of Bias in Included Studies
The McMaster Critical Review Form was chosen for critical appraisal, as it is suitable for most types of studies.19 However, as
randomized controlled trials (RCTs) were also included in the review, additional criteria to assess validity were added for these
studies. Additional criteria were not included in total and percentage scores for non-RCT studies. Critical appraisal was
undertaken independently; any disagreements were resolved by discussion and mutual consensus.
Data Extraction and Synthesis
The reviewers extracted key data in the areas of subject characteristics (gender, age, duration of symptoms),
intervention/comparator intervention given, outcome measures, and results. P-values and confidence intervals were gathered
where available to determine significance of the results. Given the heterogeneity of studies, a narrative approach was deemed as
an appropriate method to synthesise the findings of individual studies. Data from individual studies were organised according to
the outcomes identified in the criteria for considering studies.
RESULTS
Description of Studies
Results of the Search
Electronic database searching retrieved 299 journal articles related to platelet-rich plasma or elbow tendinopathies. After
removing duplicates, this was reduced to 157. After screening, 10 articles were identified as being potentially eligible and were
assessed in full-text. An overview of the search results is provided in Figure 1.

© The Internet Journal of Allied Health Sciences and Practice, 2013

The Effect of Platelet-Rich Plasma on Elbow Tendinopathies: A Systematic Review

4

Figure 1. Consort Diagram

Included Studies
Five studies met the inclusion criteria: four RCTs and one cohort study. The characteristics of the participants are given in Table
1 and the nature of the interventions and outcomes are given in Table 2. The study by Gosens et al is a two-year follow-up from
the study by Peerbooms et al.20,21

Study

Table 1. Characteristics of the Participants
Sample size
Mean age (years)
Gender

Creaney et al.
201122

PRP: 80
Blood: 70

PRP: 53
Blood: 48

Given as
percentages:
PRP: 57% M
Blood: 56% M

Mishra & Pavelko
20063

PRP:15
Control: 5

PRP: 48.1
Control: 42.2

Not reported

PRP: 15.3
Control: 11.8

Peerbooms et al.
201021

Corticosteroid: 51
PRP: 49

Corticosteroid: 47.3
PRP: 46.9

F = 52
M = 48

Not reported
(however inclusion
criteria stated
duration > 6
months)

Blood: 14
PRP: 14

Blood: 36.6
PRP: 35.9

F = 24
M=4

Blood: 5.1
PRP: 4.7

Gosens et al. 201120

Thanasas et al.
201123

PRP: platelet-rich plasma, F: female, M: male
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Table 2. Nature of the Interventions and Outcomes
Interventions
Co-interventions
Outcomes
PRP: 2 injections of Nil
PRTEE
PRP (0 months and
1 month)
Blood: 2 injections
of whole blood (0
months and 1
month)

Follow-up periods
1 month
3 months
6 months

Mishra & Pavelko
20063

PRP: 1 injection of
2-3mL of PRP
Control: 1 injection
of 2-3mL
bupivacaine with
epinephrine

Both groups given
standardized
stretching for 2
weeks, followed by
a strengthening
program (duration
not specified)

Pain (VAS)
Modified Mayo
elbow score

4 weeks
8 weeks
6 months

Peerbooms et al.
201021

Corticosteroid: 1
injection of 1mL of
corticosteroid with
bupivacaine and
epinephrine
PRP: 1 injection of
1mL of PRP
**Re-intervention
was allowed if
needed

Both groups given
standardized
stretching for 2
weeks, followed by
a strengthening
program (duration
not specified)

Pain (VAS)
DASH

4 weeks
8 weeks
12 weeks
26 weeks
52 weeks
104 weeks

Blood: 1 injection of
3mL of whole blood
PRP: 1 injection of
3mL of PRP

Both groups given
simple stretching
and eccentric
exercises to do
individually, twice
daily for 5 weeks

Pain (VAS)
Liverpool Elbow
Score

6 weeks
3 months
6 months

Gosens et al.
201120

Thanasas et al.
201123

PRP: platelet-rich plasma, VAS: visual analogue scale, PRTEE: patient rated tennis elbow evaluation, DASH: Disabilities of
the arm, shoulder and hand.
Risk of Bias in Included Studies
Critical appraisal scores for the included studies are displayed in Table 3. The article by Gosens et al was not critically appraised
separately as it was the follow-up to the Peerbooms et al study.20,21 Two studies did not describe their sample adequately and
one study did not provide a power calculation or other explanation to justify their sample size.3,22 Four out of five studies did not
describe the reliability and validity of the outcome measures they had used.20-23 The RCTs all allocated their subjects randomly;
however, none blinded the therapist and some did not blind the subjects or the assessors.20-23 Additionally, one study
administered two PRP injections and the other studies only administered one.22 The duration of symptoms across studies was
not consistent but was at least three months in each study.
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Table 3. Critical Appraisal
Creaney et al
Mishra &
201122
Pavelko 20063

NHMRC Level of evidence18
Level II
McMaster Criteria19
Clear study purpose
1
Relevant background literature
1
reviewed
Specify design
RCT
Sample described in detail
0
Sample size justified
1
Reliable outcome measures
0
Valid outcome measures
1
Interventions described in detail
1
Contamination avoided
1
Cointervention avoided
1
Results reported in terms of statistical
1
significance
Appropriate analysis methods
1
Clinical importance reported
1
Drop-outs reported
1
Appropriate conclusions
1
Additional RCT criteria
Random allocation of subjects
1
Blinding of subjects
0
Blinding of therapist
0
Blinding of assessors
0
TOTAL SCORE
13
TOTAL %
72%
RCT: randomized controlled trial, NA: not applicable

Thanasas et al
201123

Level III-2

Peerbooms et al
201021 &
Gosens et al
201120
Level II

1
1

1
1

1
1

Cohort
0
0
1
1
1
1
1
1

RCT
1
1
0
0
1
1
1
1

RCT
1
1
0
0
1
1
1
1

1
1
1
1

1
1
1
1

1
0
1
1

NA
NA
NA
NA
12
86%

1
1
0
0
14
78%

1
0
0
1
13
72%

Level II

Effects of Interventions
A quantitative synthesis of findings was not possible because of the heterogeneity of variables (i.e., intervention dosage and
frequency) and outcomes examined by individual studies. Thus, findings are presented in a narrative summary. The use of
confidence intervals and p values to report on the significance of the data was variable through the studies. None of the studies
reported on effect size.
Pain
Four studies used the Visual Analogue Scale (VAS), using pain reduction as a measure of efficacy. Mishra and Pavelko found
that there was a significant reduction in pain in the PRP group at four weeks and eight weeks compared with the control group.3
By the next follow-up period at six months, 3 out of 5 controls had dropped out, thus the PRP group could not be compared to
the controls. However, the six month follow-up of the PRP group showed a significant difference in pain from baseline.3
Thanasas and colleagues’ results showed that both the PRP and whole blood groups had improvements in pain at 6 weeks, 3
months, and 6 months.23 The PRP group had lower pain scores than the whole blood group at each re-evaluation interval;
however, the difference was only significant at 6 weeks.23
According to the Peerboom et al trial, after four weeks, the corticosteroid group’s pain worsened whereas the PRP group
continued to slowly improve; the PRP group had significantly less pain than the corticosteroid group at both 26 weeks and 52
weeks.21 This was maintained in the two-year follow-up study by Gosens et al, which showed significantly less pain in the PRP
group at 104 weeks post-injection.20
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Physical Function
While only four studies used the VAS to evaluate pain as an outcome measure, all studies also used some kind of outcome
measure for physical function; however, the measures used varied across studies, which makes comparison between studies
somewhat difficult.
Mishra and Pavelko used a modified Mayo elbow score, a measure of elbow pain, motion, stability, and function, and found there
was greater improvement in the PRP group compared with controls at both 4 and 8 weeks, but this was statistically significant
only at 8 weeks. As with the pain measure, analysis between groups at 6 months could not be completed because of the high
drop-out rate of controls. At 6 months however, the PRP group maintained a statistically significant improvement in their Mayo
elbow score from baseline.3
Thanasas et al and Creaney et al compared whole blood with PRP in terms of physical function outcomes using the Liverpool
elbow score and the Patient Rated Tennis Elbow Evaluation (PRTEE) respectively.22,23 Thanasas et al found no significant
difference at any time points between the whole blood and PRP groups in terms of physical function; however, both groups did
improve.23 Creaney et al reported both the blood and PRP groups improved at 3 months, with no significant difference between
groups. At 6 months, the blood group showed greater improvements than the plasma group. However, the authors excluded
subjects who elected to have surgery in their analysis, a greater proportion of which were in the blood group. As the authors
themselves reported, this falsely creates an impression of greater improvement in the blood group. As a result, these findings
should be interpreted with caution.22
Peerbooms et al used the Disabilities of the Arm, Shoulder and Hand (DASH) score to assess physical function. They found a
similar trend in changes of physical function to that of pain, whereby the corticosteroid group initially improved more, then
worsened, whereas the PRP group had a gradual improvement. There were no significant differences in the DASH scores
between the corticosteroid group and the PRP group until 26 weeks, when the PRP group was significantly better. This
difference was maintained at 52 weeks and again at 104 weeks in the follow-up study by Gosens et al.20,21
Adverse Effects
Only three of the studies reported on adverse effects. Thanasas and colleagues reported several subjects (9 of PRP group and 4
of whole blood group) had short-term local pain at the injection site. There were no other complications.23 Peerbooms and
colleagues reported, as did Gosens et al in the follow-up, that there were no systemic reactions, fevers, or rashes. They did,
however, discuss that local inflammation had caused an initial worsening of pain after the injection, but did not report the number
of subjects who experienced the symptoms nor their group assignments.20,21
DISCUSSION
The aim of this review was to systematically review the evidence regarding the effect and safety of platelet-rich plasma injections
for elbow tendinopathies. The evidence suggests that PRP does improve both pain and physical function in chronic elbow
tendinopathies; however, its efficacy compared with corticosteroid and autologous blood injections was variable. Overall, there is
insufficient evidence to support PRP as a first line treatment for chronic elbow tendinopathies. There is some evidence to
suggest that when considering injection therapy, PRP should be trialed before a cortisone injection and may be equally as
effective as whole blood. The two studies that reported regarding safety and adverse effects found that PRP was a safe
intervention with no significant adverse effects, although it could be argued that the cost effectiveness of PRP injections is
significantly higher than other conservative methods of treatment for elbow tendinopathies.
In the studies reviewed, all subjects had a symptom duration of at least 3 months and had not responded to other conservative
management. Thus, the results can be applied to patients with chronic elbow tendinopathies, but does not provide any indication
regarding the usefulness of PRP injections in patients with acute onset of elbow tendinopathies or as an initial treatment.
Several limitations to the current review exist due to the heterogeneity of the available studies regarding PRP and elbow
tendinopathies. The PRP intervention was not prepared and delivered in a standard manner, and the volume and frequency of
PRP injections varied across the studies. The activation of PRP and platelet growth factor release, or bioactivity, is significantly
affected by the different platelet harvesting methods used.24,25 Specifically, the concentration of platelets and presence or
absence of leukocytes in the PRP treatment may play alter the PRP’s effectiveness.3 Sampson et al suggest that this lack of
standardisation of PRP preparation protocols may theoretically affect data, presenting a limitation to the current findings.12
Variations also existed in the exercise co-interventions between studies and the detail of their description. While Thanasas and
colleagues reported that a standard rehabilitation program of stretching and eccentric loading exercises was given and indicated
the prescribed frequency, no other details of the exercise prescription were given.23 Mishra and Pavelko and Peerbooms et al
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both initiated a two week stretching protocol and then formal strengthening program; however, the authors did not detail the
specifics of the exercise prescription.3,21 Creaney et al did not state any rehabilitation program at all.22 This lack of standardized
rehabilitation protocol could potentially have contributed to the mixed results observed between studies. Additionally, the lack of
detail regarding exercise prescription within the current PRP research limits the utility of the intervention in clinical practice.
It could be argued that the use of the Liverpool Elbow Score to measure physical function by Thanasas et al was inappropriate,
as this takes into account elbow ROM and the ulnar nerve, both of which are not usually affected in lateral elbow epicondylosis.23
This may, therefore, have impacted on the lack of a significant difference between the PRP and whole blood groups in this study.
The different choices of outcome measures for physical function between studies certainly limited the ability to synthesise the
results and draw conclusions.
At an individual level within the studies, some methodological flaws existed. Two studies had particularly small sample sizes, and
the level of blinding in the RCTs was inadequate. The cohort study has limitations in its results based upon the study design, and
thus lack of blinding or randomization. The statistical analyses conducted did not consistently present p-values for statistical
significance or confidence intervals, and no study reported on effect sizes.
CONCLUSIONS
Implications for Practice
The implication of the limitations of the available literature is that it is difficult to determine how much of an effect PRP has on
elbow tendinopathies, and it is not possible to make recommendations regarding a standard process of PRP preparation and
prescription to achieve the best outcomes.
There is insufficient evidence to recommend the use of PRP injections over other modalities for the treatment of elbow
tendonopathies. However, this review has demonstrated that there is enough evidence to suggest the use of PRP may be
beneficial for both pain and physical function within presentations of chronic elbow tendinopathies, especially those longer than 3
months duration. This review has also demonstrated that PRP injections should be trialed before corticosteroid injections and
that PRP injections provide another conservative treatment approach that can be trialed before surgery.
Implications for Research
Further randomised controlled trials investigating the efficacy of PRP injections versus whole blood, cortisone injections, or any
other modality, or one injection versus multiple injections, for elbow tendonopathies are required before this treatment can be
routinely recommended. Further research should also investigate PRP injections versus a placebo. It would be of benefit if future
research was conducted with greater sample sizes of more specific populations, greater randomization, and a standard
preparation of the PRP. Both pain and physical function, inclusive of level of difficulty with functional activities, should be
measured with the use of appropriate outcome measures and a clearly defined rehabilitation program within each trial.
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